Specific Biologics
Specific Biologics Inc. (SBI) is dedicated to developing novel gene editing technologies to treat diseases at the genetic level within cells inside the body. Their platform technology, Dualase, is a dual-cleaving nuclease designed to improve DNA repair outcomes and target genetic diseases previously unaddressable. SBI is actively building a pipeline of therapeutics based on this technology, collaborating through licensing and partnerships, and is located in the MaRS Centre in Toronto. The company is committed to advancing gene editing solutions to improve patient lives.
Industries
Nr. of Employees
small (1-50)
Patents
Products
Dual-cleaving nuclease-based gene editing platform
A gene editing platform that introduces two DNA cuts and leaves non-compatible ends to influence cellular repair pathways for therapeutic editing inside somatic cells.
Dual-cleaving nuclease-based gene editing platform
A gene editing platform that introduces two DNA cuts and leaves non-compatible ends to influence cellular repair pathways for therapeutic editing inside somatic cells.
Services
Partnering, licensing, and co-development opportunities focused on technologies that improve nuclease function or delivery for somatic cell gene editing.
Partnering, licensing, and co-development opportunities focused on technologies that improve nuclease function or delivery for somatic cell gene editing.
Expertise Areas
- Gene editing platform development
- DNA repair pathway engineering
- Preclinical therapeutic development for genetic diseases
- In vivo somatic cell delivery
Key Technologies
- Engineered dual-cleaving nucleases
- Generation of non-compatible DNA ends
- Modulation of endogenous DNA repair pathways
- Template-directed repair enhancement